Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Vaxcyte, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 265 | 2 | 329 | +66 |
| Shares | 122.6M | 9.94M | 136.5M | +23.9M (+21.2%) |
| Value | $9.26B | $750.6M | $15.6B | +$7.08B (+83.2%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (86)
Institutions that held Vaxcyte, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (20)
Institutions that held Vaxcyte, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Avidity Partners Management LP | 284,000 | $21.4M |
| First Light Asset Management, LLC | 139,729 | $10.6M |
| Eversept Partners, LP | 96,089 | $7.26M |
| Adage Capital Partners GP, L.L.C. | 85,088 | $6.42M |
| Erste Asset Management GmbH | 33,600 | $2.65M |
| Parkwood LLC | 11,702 | $884.0K |
| Eisler Capital (US) LLC | 10,454 | $789.4K |
| Kennedy Capital Management, Inc. | 6,252 | $472.1K |
| Toroso Investments, LLC | 5,397 | $407.5K |
| Crossmark Global Holdings, Inc. | 3,672 | $277.0K |
| Assenagon Asset Management S.A. | 2,826 | $213.4K |
| J. Goldman & Co LP | 2,700 | $203.9K |
| Group One Trading, L.P. | 2,473 | $186.7K |
| Quest Partners LLC | 926 | $69.9K |
| Pacer Advisors, Inc. | 539 | $40.7K |
| SYSTM Wealth Solutions LLC | 306 | $23.1K |
| Rakuten Securities, Inc. | 258 | $19.5K |
| Innealta Capital, LLC | 45 | $3.40K |
| FinTrust Capital Advisors, LLC | 27 | $2.04K |
| Lynx Investment Advisory | 26 | $1.96K |
Not filed for Q3 2024 yet (2)
Institutions that held Vaxcyte, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 9,939,846 | $750.6M |
| Institutional & Family Asset Management, LLC | 13 | $982 |